Program
Anti-CALRmut/Anti-CD3 Bispecific Antibody JNJ-88549968
Its studies are mostly in Neoplasms, led by Johnson & Johnson.
Furthest: phase 1, since Nov 21, 20231 company-led study, 1 open or runningNext primary completion: Jun 14, 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Johnson & Johnson | 11 open or running | phase 1since Nov 21, 2023 | Nov 21, 2023 | Jun 14, 2027phase 1 · NCT06150157 |
- Named in Johnson & Johnson’s own pipeline as
JNJ-9968
, phase 1, as of Oct 13, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 21, 2023First study: phase 1 study in NeoplasmsFirst studyNCT06150157 · 300 planned · United States, Canada, China and more
- Oct 26, 2026Primary completion moved from 2026-12-04 to 2027-06-14Date moved laterphase 1 · +6 months · NCT06150157
Ahead
- Jun 14, 2027Primary completion: phase 1 study in NeoplasmsNCT06150157
TargetBeta
“A bispecific antibody directed against both the mutated form of calreticulin (CALRmut; mutCALR) and the T-cell surface antigen CD3, with potential immunostimulating and antineoplastic activities. Upon administration, anti-CALRmut/anti-CD3 bispecific antibody JNJ-88549968 targets and binds to both…”NCIt, read by Claude
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06150157Neoplasms · United States, Canada, China and more | 1 | Recruiting | Jun 14, 2027 | 300 |
How it is read
Names in the registry
- “JNJ-88549968”, 1 entry
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.